{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=28",
    "query": {
      "intervention": "Random Match",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 5391,
    "total_pages": 540,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Random+Match&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T09:43:52.928Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03811912",
      "title": "Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "CTP-543",
          "type": "DRUG"
        },
        {
          "name": "CTP-543 Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Concert Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 57,
      "start_date": "2019-03-21",
      "completion_date": "2019-11-21",
      "has_results": true,
      "last_update_posted_date": "2022-12-09",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 10,
      "location_summary": "Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03811912"
    },
    {
      "nct_id": "NCT04251182",
      "title": "Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "15mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "30 mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "45 mg T3D-959",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "T3D Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 250,
      "start_date": "2021-03-01",
      "completion_date": "2023-02-17",
      "has_results": false,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04251182"
    },
    {
      "nct_id": "NCT05065359",
      "title": "Multiple-Ascending Dose in Japanese Patients Bridging Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rodatristat Ethyl 300 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Rodatristat Ethyl 600 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Altavant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 47,
      "start_date": "2021-10-01",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2022-07-13",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05065359"
    },
    {
      "nct_id": "NCT05626803",
      "title": "A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus Infections"
      ],
      "interventions": [
        {
          "name": "Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose",
          "type": "DRUG"
        },
        {
          "name": "Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose",
          "type": "DRUG"
        },
        {
          "name": "Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 135,
      "start_date": "2023-01-26",
      "completion_date": "2023-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 3,
      "location_summary": "Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05626803"
    },
    {
      "nct_id": "NCT01817959",
      "title": "Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Islet Transplantation in Diabetes Mellitus Type 1"
      ],
      "interventions": [
        {
          "name": "Reparixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 51,
      "start_date": "2012-10",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817959"
    },
    {
      "nct_id": "NCT03243162",
      "title": "Improving ACL Reconstruction Outcomes: CBPT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ACL Injury",
        "ACL - Anterior Cruciate Ligament Rupture",
        "ACL Sprain",
        "ACL Tear"
      ],
      "interventions": [
        {
          "name": "CBPT-ACLR",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "14 Years to 35 Years"
      },
      "enrollment_count": 90,
      "start_date": "2017-07-01",
      "completion_date": "2020-04-17",
      "has_results": false,
      "last_update_posted_date": "2020-05-20",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 2,
      "location_summary": "Garfield Heights, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Garfield Heights",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03243162"
    },
    {
      "nct_id": "NCT05123586",
      "title": "A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "LY3361237",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 85,
      "start_date": "2022-03-07",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 19,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05123586"
    },
    {
      "nct_id": "NCT04019041",
      "title": "A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa",
        "Acne Inversa",
        "Suppurative Hidradenitis"
      ],
      "interventions": [
        {
          "name": "bermekimab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2019-09-16",
      "completion_date": "2020-11-17",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 33,
      "location_summary": "Gilbert, Arizona • Huntington Beach, California • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019041"
    },
    {
      "nct_id": "NCT07229482",
      "title": "Potatoes, Type 2 Diabetes, and Cardiometabolic Health",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "T2D",
        "Blood Pressure",
        "Cardiometabolic Health"
      ],
      "interventions": [
        {
          "name": "Controlled diet: Potato-rich healthy dietary pattern",
          "type": "OTHER"
        },
        {
          "name": "Controlled diet: Typical Western-style dietary pattern",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Virginia Polytechnic Institute and State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2026-08-27",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 1,
      "location_summary": "Blacksburg, Virginia",
      "locations": [
        {
          "city": "Blacksburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07229482"
    },
    {
      "nct_id": "NCT02708186",
      "title": "Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies",
        "REM Sleep Behavior Disorder",
        "Parkinson's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Nelotanserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axovant Sciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2016-03",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2020-05-20",
      "last_synced_at": "2026-10-26T09:43:52.928Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02708186"
    }
  ]
}